In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), with a ...

William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market ...

Fintel reports that on March 10, 2025, Guggenheim downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by investment ...

Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal ...

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA ...

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action ...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...

Neumora Therapeutics (NMRA) surprised investors in its Q4 2024 earnings call by reporting an earnings per share (EPS) of -$0.37, surpassing the forecasted -$0.62. This unexpected result led to a ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora ...